This hypothesis is supported by evidence driven by experimental models where treatment with nivolumab and pembrolizumab gave poor results in mice with NASH characterized by PD-1 overexpression. This evidence concerns the gene PDCD1 and metabolic dysfunction-associated steatohepatitis.